Metal-based antitumour drugs in the post genomic era

被引：741

作者：

Dyson, PJ ^{[1
]}

Sava, G

机构：

[1] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland

[2] Callerio Fdn Onlus, I-34127 Trieste, Italy

[3] Univ Trieste, Dipartimento Sci Biomed, I-34127 Trieste, Italy

来源：

DALTON TRANSACTIONS | 2006年 / 16期

关键词：

D O I：

10.1039/b601840h

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The discovery of new metal-based antitumour drugs, whether cisplatin derivatives or those based on other metals, has been largely based on cell viability assays (IC50 values) and compounds that bind to DNA. This approach has been applied for more than 30 years during which time very few new drugs have entered clinical use. In this article we discuss what the future holds for metal-based drugs, in particular anti-metastasis drugs, in these enlightened times of the post genomic era.

引用

页码：1929 / 1933

页数：5

共 44 条

[1] Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA=1,3,5-triaza-7-phosphaadamantane) [J].

Akbayeva, DN ;

Gonsalvi, L ;

Oberhauser, W ;

Peruzzini, M ;

Vizza, F ;

Brüggeller, P ;

Romerosa, A ;

Sava, G ;

Bergamo, A .

CHEMICAL COMMUNICATIONS, 2003, (02) :264-265

[2] Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systems [J].

Allardyce, CS ;

Dyson, PJ ;

Abou-Shakra, FR ;

Birtwistle, H ;

Coffey, J .

CHEMICAL COMMUNICATIONS, 2001, (24) :2708-2709

[3] Development of organometallic (organo-transition metal) pharmaceuticals [J].

Allardyce, CS ;

Dorcier, A ;

Scolaro, C ;

Dyson, PJ .

APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10

[4] Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties [J].

Allardyce, CS ;

Dyson, PJ ;

Ellis, DJ ;

Salter, PA ;

Scopelliti, R .

JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2003, 668 (1-2) :35-42

[5] [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane):: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells [J].

Allardyce, CS ;

Dyson, PJ ;

Ellis, DJ ;

Heath, SL .

CHEMICAL COMMUNICATIONS, 2001, (15) :1396-1397

[6] Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance [J].

Ang, WH ;

Khalaila, I ;

Allardyce, CS ;

Juillerat-Jeanneret, L ;

Dyson, PJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (05) :1382-1383

[7] The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation [J].

Bacac, M ;

Hotze, ACG ;

van der Schilden, K ;

Haasnoot, JG ;

Pacor, S ;

Alessio, E ;

Sava, G ;

Reedijk, J .

JOURNAL OF INORGANIC BIOCHEMISTRY, 2004, 98 (02) :402-412

[8] Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes [J].

Barnes, KR ;

Kutikov, A ;

Lippard, SJ .

CHEMISTRY & BIOLOGY, 2004, 11 (04) :557-564

[9]

Bergamo A, 1999, J PHARMACOL EXP THER, V289, P559

[10] Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue [J].

Biot, C ;

Glorian, G ;

Maciejewski, LA ;

Brocard, JS ;

Domarle, O ;

Blampain, G ;

Millet, P ;

Georges, AJ ;

Abessolo, H ;

Dive, D ;

Lebibi, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (23) :3715-3718

← 1 2 3 4 5 →